Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis

 

 Buy Article Permissions and Reprints

Summary

Antithrombin (AT), in the presence of heparin, is able to inhibit the catalytic activity of factor VIIa bound to tissue factor (TF) on cell surfaces. The clinical meaning of FVIIa-AT complexes plasma levels is unknown. It was the objective of this study to evaluate FVIIa-AT complexes in subjects with thrombosis. Factor VIIa-AT complexes plasma levels in 154 patients consecutively referred to our Department with arterial or venous thrombosis and in a group of 154 healthy subjects, were measured. Moreover, FVIIa-AT complexes were determined in: i) n = 53 subjects belonging to 10 families with inherited factor VII deficiency; ii) n = 58 subjects belonging to seven families with AT deficiency; iii) n = 49 patients undergoing oral anticoagulant therapy (OAT). Factor VIIaAT levels were determined by a specific ELISA kit (R&D, Diagnostica Stago, Gennevilliers, France). Factor VIIa-AT complexes mean plasma levels were lower in patients with either acute arterial (136 ± 40 pM) or venous (142 ± 53 pM) thrombosis than subjects with previous thrombosis (arterial 164 ± 33 pM and venous 172 ± 61 pM, respectively) and than healthy controls (156 ± 63 pM). Differences between acute and previous thrombosis, were statistically significant (p < 0.05). Subjects with inherited and acquired (under OAT) factor VII deficiency had statistically significant lower FVIIa-AT complexes plasma levels (80 ± 23 pM and 55 ± 22 pM, respectively) than controls (150 ± 51 pM, p < 0.0001 and 156 ± 63 pM, p < 0.00001, respectively). Factor VIIa-AT complexes are positively correlated with plasma factor VII/VIIa levels. Further investigations are needed to verify the possible role of higher FVIIa-AT complex plasma levels in predicting hypercoagulable states and thrombosis.

• References

• 1 Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 1985; 40: 351-358.
  CrossrefPubMedGoogle Scholar
• 2 Broze GJ Jr, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochem 1990; 29: 7539-7546.
  CrossrefPubMedGoogle Scholar
• 3 Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Salemink I, Franssen J, Willems GM. et al. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost 1998; 80: 273-280.
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Bajaj MS, Birktoft JJ, Steer SA. et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-972.
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 Kondo S, Kisiel W. Regulation of factor VIIa activity in plasma: evidence that anti-thrombin III is the sole plasma protease inhibitor of human factor VIIa. Thromb Res 1987; 46: 325-335.
  CrossrefPubMedGoogle Scholar
• 7 Rao LV, Rapaport SI, Hoang AD. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 1993; 81: 2600-2607.
  PubMedGoogle Scholar
• 8 Lawson JH, Butenas S, Ribarik N. et al. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 1993; 268: 767-770.
  PubMedGoogle Scholar
• 9 Broze GJ Jr, Likert K, Higuchi D. Inhibition of factor VIIa/tissue factor by anti-thrombin III and tissue factor pathway inhibitor. Blood 1993; 82: 1679-1680.
  PubMedGoogle Scholar
• 10 Jesty J, Lorenz A, Rodriguez J. et al. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood 1996; 87: 2301-2307.
  PubMedGoogle Scholar
• 11 Iakhiaev A, Ruf W, Rao LV. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor. Thromb Haemost 2001; 85: 458-463.
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Rao LV, Nordfang O, Hoang AD. et al. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-129.
  PubMedGoogle Scholar
• 13 Smith SA, Antonaci FC, Woodhams BJ. et al. Factor VIIA-antithrombin complexes in human plasma. XXI Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland, July 2007. J Thromb Haemost 2007 05. (Suppl 2): Abstract O-S-040.
  PubMedGoogle Scholar
• 14 Miller GJ, Ireland HA, Cooper JA. et al. Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost 2008; 06: 259-267.
  CrossrefPubMedGoogle Scholar
• 15 Bilgen D, Sönmez H, Ekmekci H. et al. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. Cl Bioch 2005; 38: 92-96.
  PubMedGoogle Scholar
• 16 Roubey RAS, Lovell T, Morrissey JH. Elevated plasma levels of factor VIIA-anti-thrombin complexes in patients with antiphospholipid antibodies. XXI Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland, July 2007. J Thromb Haemost. 2007 05. (Suppl 2): Abstract P-T-431.
  PubMedGoogle Scholar